The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans

Insulin Resistance Clinical Trial

Official title:

The Effect of Daily Dietary Supplementation With Cranberry Extract on Modulation of Cardiovascular Risk Factors in Obese, Insulin Resistant Human Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02068144
• Other study ID #: PBRC 2013-047
• Status: Completed
• Phase: N/A
• Start date: February 2014
• Est. completion date: July 11, 2018

Study information

• Verified date: August 2018
• Source: Pennington Biomedical Research Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the health benefits of cranberry extract in people who are at risk for diabetes and heart problems.

Description:

This study will be a double-blinded, randomized, placebo-controlled, pilot study in which subjects with pre-diabetes will be randomized to receive either placebo or Cranberry extract for a total of 8 weeks of treatment. Each subject will continue on the same dosage of cranberry extract or matching placebo for the entire duration of treatment. Comparisons for insulin sensitivity, endothelial function, and markers of inflmmation and oxidative stress will be made between the 2 groups pre and post intervention.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: July 11, 2018
• Est. primary completion date: June 2, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Are 20 years of age or older

• Not being treated with diabetes medication. However, if you are taking Metformin for pre-diabetes and are willing to stop taking the medication 2 weeks before and during the study that is ok. We will request clearance from your prescribing physician prior to stopping metformin and enrolling in the study.

• Have a blood sugar of 100-125 mg/dL (fasting) or 140-199 mg/dL after a 2 hour glucose tolerance test (determined by tests done at the screening visit)

• Have a fasting insulin more than or equal to 5 µIU/ml (determined by tests done at the screening visit)

• Have a Body Mass Index (BMI) = 30 and = 45.

Exclusion Criteria:

• Have a prior history of type 2 diabetes

• Are pregnant or breastfeeding.

• Are a woman able to have children and are not using birth control (i.e. barrier method, intrauterine and cervical devices, birth control pills, hormonal injections (Depo Provera® ), condoms with spermicidal gel or foam, contraceptive patch (Ortho Evra), diaphragm, or abstinence), or have had a tubal ligation or hysterectomy, or not at least 2 years past menopause.

• All women able to have children will have a pregnancy test at the screening visit. If you become pregnant during the study, you will be dropped from the study.

• Have type 1 diabetes.

• Are taking steroids (except topical or inhaled steroids).

• Other medications that may affect your blood sugar (i.e. certain blood pressure medications) are acceptable if the dose has not changed in the previous 6 months and the dose will not change during the study.

• Have a history or evidence of stomach or intestinal problems, e.g. irritable bowel syndrome; inflammatory bowel disease; ulcerative colitis or Crohn's disease; diverticulosis or diverticulitis; narrowing of the intestines, partial or complete removal of the stomach or small bowel; autonomic neuropathy consisting of difficulty swallowing; delayed stomach emptying or diarrhea; chronic, severe constipation; stomach or colon ulcers, or GI bleeding.

• Use laxatives or cathartics on a chronic basis.

• Take medications known to damage the kidneys, such as certain antibiotics, methicillin, and cyclosporin.

• Have any evidence of kidney disease.

• Have significant heart problems and/or history (within the last 6 months) of significant heart problems.

• Have evidence within the previous 6 months of liver disease such as hepatitis; jaundice; cirrhosis.

• Have clinically significant lung, neurologic, blood-related, immune system-related, cancer-related or metabolic disease.

• Have had a recurrence of cancer within the past five years, other than treated basal cell carcinoma.

• Are planning surgery during the study period.

• Have a history of substance abuse or alcoholism within the past 5 years, or significant psychiatric disorder that would interfere with your ability to complete the study.

• Have donated blood during the month before entering the study or are planning to donate blood during the study.

• Have participated in other studies using a research medication during the previous 3 months.

• Are currently smoking or have smoked within the past 6 months.

• No smoking will be allowed during the study.

• Have had a fluctuation in body weight >5% in the previous 2 months.

• Are taking prescription or over-the-counter medication for weight loss.

• Are taking weight loss or herbal supplements.

• Are taking prescription or over-the-counter anti-inflammatory medications (such as naproxen, aspirin, ibuprofen).

• Are allergic to cranberries

Related Conditions & MeSH terms

• Atherosclerosis
• Insulin Resistance

Intervention

Dietary Supplement:
• Cranberry Extract
Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.

Other:
• Placebo
Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.

Locations

Country	Name	City	State
United States	Pennington Biomedical Research Center	Baton Rouge	Louisiana

Sponsors (2)

Lead Sponsor	Collaborator
Pennington Biomedical Research Center	Ocean Spray, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline Hyperinsulinemic-Euglycemic clamp at week 8	Insulin sensitivity is tested using a 120 mU/m2 hyperinsulinemic-euglycemic clamp at 100mg/dL glucose over 2 hours at weeks 0 and 8	8 weeks +/- 2 days
Secondary	Change from baseline in endothelial function at week 7	Endothelial function by peripheral arterial tone (PAT) with an endo-PAT device prior to week 0 and week 7 as a surrogate measure of atherosclerosis.	8 weeks +/- 2 days
Secondary	Change from baseline in Indirect Calorimetry at week 8	Resting metabolic rate via indirect calorimetry will be measured using a Deltatrac II Metabolic cart at week 0 and week 8 as part of the hyperinsulinemic euglycemic clamp.	8 weeks +/- 2 days
Secondary	Change from screening to week 8 in lipid profile	A comprehensive metabolic profile (CHEM 15) will be obtained at screening and then at week 8.	10 weeks +/- 2 days
Secondary	Change in body weight from baseline to week 8	Body weight will be assessed at baseline and week 8.	8 weeks +/- 2 days
Secondary	Change from screening to week 7 in oral glucose tolerance test (OGTT)	A 2 hr OGTT will be performed prior to week 0 and at week 7	8 weeks +/- 2 days
Secondary	Change in nitric oxide level at baseline and week 8	Levels of nitric oxide will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in endothelin 1 level at baseline and week 8	Levels of endothelin 1 will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in oxidized LDL level at baseline and week 8	Levels of oxidized LDL will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in LOX-1 (Lectin-like oxidized low density lipoprotein-1) at baseline and week 8	Levels of LOX-1 (Lectin-like oxidized low density lipoprotein-1) will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in 8-isoprostanes at baseline and week 8	Levels of 8-isoprostanes will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in malondialdehyde at baseline and week 8	Levels of malondialdehyde will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in advanced glycation end products at baseline and week 8	Levels of advanced glycation end products will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in Apo A1 at baseline and week 8	Levels of Apo A1 will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in Paraoxonase at baseline and week 8	Levels of Paraoxonase will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in Adiponectin at baseline and week 8	Levels of Adiponectin will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in C-reactive protein (CRP) at baseline and week 8	Levels of C-reactive protein (CRP) will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days
Secondary	Change in TNFa at baseline and week 8	Levels of TNFa will be assessed at baseline and after 8 weeks of intervention	8 weeks +/- 2 days